Table 4.

Univariate analysis for candidate prognostic factors using Cox proportional hazards model

Candidate factorPFSOS
Hazard ratio (95% CI)PHazard ratio (95% CI)P
GHSG risk score    .036 
 Low Reference group  Reference group 
 Intermediate 6.72 (0.87-52.01) .068 No events 
 High 6.02 (0.72-50.45) .098 No events 
ECOG performance status (1 vs 0) 0.97 (0.90-2.40) .94 1.19 (0.33-4.23) .79 
Stage III/IV vs I/II 1.22 (0.50-3.00) .66 1.17 (0.33-4.41) .81 
Male sex 5.08 (1.17-22.00) .008 >100* .006 
B symptoms 1.76 (0.63-4.94) .28 1.20 (0.25-5.70) .82 
Splenic involvement 6.94 (2.07-23.26) .002 1.57 (0.33-7.50) .57 
Bone marrow involvement 1.60 (0.46-5.61) .46 0.77 (0.10-6.20) .81 
Transformed histology at diagnosis 0.49 (0.06-3.80) .50 <0.01* .21 
Albumin < 4.0 g/dL 1.41 (0.46-4.31) .54 0.92 (0.19-4.42) .92 
Histologic variant (non-A/B†) 1.04 (0.39-2.77) .94 10.4 (0.27-4.04) .95 
Candidate factorPFSOS
Hazard ratio (95% CI)PHazard ratio (95% CI)P
GHSG risk score    .036 
 Low Reference group  Reference group 
 Intermediate 6.72 (0.87-52.01) .068 No events 
 High 6.02 (0.72-50.45) .098 No events 
ECOG performance status (1 vs 0) 0.97 (0.90-2.40) .94 1.19 (0.33-4.23) .79 
Stage III/IV vs I/II 1.22 (0.50-3.00) .66 1.17 (0.33-4.41) .81 
Male sex 5.08 (1.17-22.00) .008 >100* .006 
B symptoms 1.76 (0.63-4.94) .28 1.20 (0.25-5.70) .82 
Splenic involvement 6.94 (2.07-23.26) .002 1.57 (0.33-7.50) .57 
Bone marrow involvement 1.60 (0.46-5.61) .46 0.77 (0.10-6.20) .81 
Transformed histology at diagnosis 0.49 (0.06-3.80) .50 <0.01* .21 
Albumin < 4.0 g/dL 1.41 (0.46-4.31) .54 0.92 (0.19-4.42) .92 
Histologic variant (non-A/B†) 1.04 (0.39-2.77) .94 10.4 (0.27-4.04) .95 

Analysis of PFS is restricted to patients for whom treatment details are known. OS analysis includes all patients with follow-up data. Boldface type indicates a significant P value.

*

Unable to generate 95% CI.

†

As defined by Hartmann et al.8 

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal